EUVIMEDEUVIMED entdecken
Crossref

Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer

Rita Ribeiro, Jorge M B Vítor, Anastasiya Voronovska, João N Moreira iD, João Goncalves

Biotechnology Journal · 2025

DOI: 10.1002/biot.202400380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Rita Ribeiro und 4 weiteren Autor:innen. Beteiligte Einrichtung: CNC-UC-Center for Neurosciences and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine (Polo 1), Universit…. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Triple Negative Breast Neoplasms, Phosphoproteins, Antibody-Dependent Cell Cytotoxicity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Pharmaceutical Sciences PhD program from the Faculty of Pharmacy, University of Coimbra, FCT - Fundação para a Ciência e a Tecnologia, I.P., CIBB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that remains an unmet medical need. Because TNBC cells do not express the most common markers of breast cancers, there is an active search for novel molecular targets in triple‐negative tumors. Additionally, this subtype of breast cancer presents strong immunogenic characteristics which have been encouraging the development of immunotherapeutic approaches against the disease. In this context, nucleolin arises as a promising target for immunotherapy against TNBC. Our group has previously developed an anti‐nucleolin VHH‐Fc antibody capable of eliciting antibody‐dependent cellular cytotoxicity (ADCC). Moreover, we constructed and characterized an antibody library, that was screened against nucleolin‐overexpressing cells, originating an enriched anti‐nucleolin antibody pool. In this work, a strategy to select individual clones from the pool was designed, combining NGS data with 3D modeling. Two antibodies demonstrated a significant 4.4‐ and 6.1‐fold increase in binding to nucleolin‐overexpressing and TNBC cells, and an improvement in affinity to the sub‐micromolar range (0.19 µM and 83.69 nM). Additionally, an increment in 4.6‐ and 3.1‐fold in ADCC activity against respective cell lines was observed for the M2 antibody clone. Herein, the affinity maturation strategy developed was validated and corroborated a positive, but not proportional, correlation between antibody binding, affinity, and ADCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsTriple Negative Breast NeoplasmsPhosphoproteinsAntibody-Dependent Cell CytotoxicityAntibody AffinityNucleolinHumansCell Line, TumorFemale

Stichwörter der Autor:innen

affinityantibody‐dependent cellular cytotoxicitymonoclonal antibodiesnucleolintriple‐negative breast cancer

Substanzen

NucleolinRNA-Binding ProteinsPhosphoproteins

Autor:innen und Institutionen

  • CNC-UC-Center for Neurosciences and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine (Polo 1), University of Coimbra, Coimbra, Portugal.
  • Faculty of Pharmacy, iMed.ULisboa - Research Institute for Medicines, University of Lisbon, Lisbon, Portugal.
  • Univ Coimbra - University of Coimbra, CIBB, Faculty of Pharmacy, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, University of Coimbra, Coimbra, Portugal.
  • Pathogen Genome Bioinformatics and Computational Biology, Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.

ORCID-Profile: João N Moreira

Förderung

  • Pharmaceutical Sciences PhD program from the Faculty of Pharmacy, University of Coimbra
  • FCT - Fundação para a Ciência e a Tecnologia, I.P.
  • CIBB
  • Fundación La Caixa BREAST-BRAIN-N-BBB 200021
  • CInTech - Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
  • Component C5 - Capitalisation and Business Innovation
  • NextGenerationEU Fund - Portuguese Resilience and Recovery Plan (PRR) - PRR-30, and PRR Bio-Hub
  • Fundación La Caixa

Zitieren

APA

Ribeiro, R., Vítor, J. M. B., Voronovska, A., Moreira, J. N., & Goncalves, J. (2025). Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer. Biotechnology Journal. https://doi.org/10.1002/biot.202400380

Vancouver

Ribeiro R, Vítor JMB, Voronovska A, Moreira JN, Goncalves J. Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer. Biotechnology Journal. 2025. doi:10.1002/biot.202400380

BibTeX
@article{Ribeiro2025,
  author = {Ribeiro, Rita and Vítor, Jorge M B and Voronovska, Anastasiya and Moreira, João N and Goncalves, João},
  title = {Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer},
  journal = {Biotechnology Journal},
  year = {2025},
  doi = {10.1002/biot.202400380}
}
Kostenlos starten →